The market for open-angle glaucoma is forecasted to experience consistent growth in the coming years. This growth is primarily fueled by the increasing global prevalence of glaucoma, attributed to aging populations, and a heightened focus on early detection. The market is also expected to benefit from the introduction of new therapies like Citicolinem, PA5108, and AGN-193408 SR. These advancements are crucial as an estimated 60 million people worldwide are affected by glaucoma, and with an aging population, this number is projected to increase substantially in the near future. The introduction of these emerging therapies is expected to address the needs of patients with open-angle glaucoma and potentially improve treatment outcomes.